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Background: The long-term aim of developing a laser based acceleration of protons and ions towards clinical
application requires not only substantial technological progress, but also the radiobiological characterization of the
resulting ultra-short pulsed particle beams. Recent in vitro data showed similar effects of laser-accelerated versus
“conventional” protons on clonogenic cell survival. As the proton energies currently achieved by laser driven
acceleration are too low to penetrate standard tumour models on mouse legs, the aim of the present work
was to establish a tumour model allowing for the penetration of low energy protons (~ 20 MeV) to further
verify their effects in vivo.
Methods: KHT mouse sarcoma cells were injected subcutaneously in the right ear of NMRI (nu/nu) mice and
the growing tumours were characterized with respect to growth parameters, histology and radiation response.
In parallel, the laser system JETI was prepared for animal experimentation, i.e. a new irradiation setup was
implemented and the laser parameters were carefully adjusted. Finally, a proof-of-principle experiment with
laser accelerated electrons was performed to validate the tumour model under realistic conditions, i.e. altered
environment and horizontal beam delivery.
Results: KHT sarcoma on mice ears showed a high take rate and continuous tumour growth after reaching a
volume of ~ 5 mm3. The first irradiation experiment using laser accelerated electrons versus 200 kV X-rays was
successfully performed and tumour growth delay was evaluated. Comparable tumour growth delay was found
between X-ray and laser accelerated electron irradiation. Moreover, experimental influences, like anaesthesia
and positioning at JETI, were found to be negligible.
Conclusion: A small animal tumour model suitable for the irradiation with low energy particles was
established and validated at a laser based particle accelerator. Thus, the translation from in vitro to in vivo
experimentation was for the first time realized allowing a broader preclinical validation of radiobiological
characteristics and efficacy of laser driven particle accelerators in the future.
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Due to their physical properties, like the inverse dose
profile in tissue with an energy dependent dose deposition
maximum (Bragg peak) at the end of their range,
radiotherapy with protons and light ions is widely accepted
to have a high potential for improving cancer treatment.
However, the present accelerator technique for protons
and ions demands huge buildings and high investment
costs that prevent their widespread clinical application. As
one potential alternative to the classical electromagnetic
accelerators, particle acceleration by means of high
intensity laser is under investigation [1,2]. This includes
not only the technological development of high intensity
lasers [3], but also extensive translational research to
transfer laser based particle accelerators to clinical
application. Compared to conventionally accelerated
particle beams, the laser driven beams are particularly
characterized by ultra-short (~ ps) particle pulses (bunches)
with an ultra-high pulse dose rate (~ 1012 Gy min-1), beside
broad energy spectra, low pulse frequency (repetition rate)
and substantial intensity (charge) fluctuations from pulse
to pulse. Along with the evaluation of dose delivery
(beam transport and monitoring, dosimetry) and quality
assurance, the biological effects on cell survival and
tumour growth of laser driven particle beams have to be
investigated for the whole translational research chain
from basic cell experiments to animal studies and finally
clinical trials [4].
Several groups have performed in vitro studies on the
radiobiological effectiveness of laser accelerated electrons
[5] and protons [6-10]. Summarizing these studies,
no significant differences have been revealed in the
radiobiological response of laser driven particle beams
relative to conventional accelerated particle beams [5-10].
Similar results were obtained using a Tandem accelerator
to mimic and compare the pulse dose rates of laser
driven and conventional proton beams [11,12]. If
these results can be validated in vivo, the findings
would allow transferring the existing database on RBE
(relative biological effectiveness) values of conventional
accelerated particle beams to their laser driven equivalents.
So far no in vivo data have been published on laser
accelerated particles. A major limitation for the in vivo
application is the delivery of particle energies high
enough to fully penetrate standard experimental tumours.
Particularly, for laser accelerated protons, the available
maximum energies of ~ 20 MeV are still too low for the
homogeneous irradiation of a tumour transplanted into
experimental animals. In consequence, the aim of the
present study is the establishment of a tumour model
that is small enough to be fully penetrated by ~ 20 MeV
protons. For this, KHT mouse sarcoma cells were injected
subcutaneously in mouse ears and the growing tumours
were characterized with respect to growth parameters andhistology; their radiation response was determined after
200 kV X-ray irradiation.
Finally, the applicability of the tumour model for
systematic experiments at a laser accelerator was validated
under the realistic and challenging conditions, like
horizontal beam delivery and altered environment, at
the experimental laser system JETI (Jena Titanium:
Sapphire [13,14]). Although the new tumour model was
motivated by future proton trials, the proof-of-principle
experiment was performed with laser accelerated electrons,
since the homogeneous delivery of prescribed doses to a
3D target volume is easier for electrons than for protons.
Therefore, a complete irradiation setup including beam
transport and control, tumour positioning and delivery of
prescribed doses was implemented at JETI [15]. In parallel
to the JETI laser experiments, animal irradiation with
200 kV X-rays were performed providing reference
data for the laser electrons and establishing a relation to
previous 200 kV X-ray data.
Methods
Animals and tumour model
All experiments were performed using 7-to-14-week-old
female and male NMRI (nu/nu) mice continuously
purchased from the Experimental Centre of the Medical
Faculty of the Technische Universität Dresden. The animal
facilities and the experiments at both experimental
places in Dresden and Jena were approved according
to the corresponding institutional guidelines and the
German animal welfare regulations. The animal housing
provided a 12 h light - 12 h dark cycle, a constant
temperature of 26°C and a relative humidity of 50–60%.
The mice were fed with commercial laboratory animal diet
and water ad libitum. In order to further suppress their
immune response, the mice were whole-body irradiated
(WBI) with 4 Gy (200 kV X-rays, 20 mA, ~ 1 Gy min-1)
two to four days before cell injection.
The KHT mouse sarcoma, originally described by
Kallman et al. [16], was kindly provided by Richard
Hill from the Ontario Cancer Institute in Toronto,
Canada, for the present experiments. KHT cells were
maintained in AlphaMEM with nucleosides supplemented
with 10% FCS (foetal calf serum) and with 2 mM L-Ala-
nyl-L-Glutamin (all from Biochrom AG, Berlin, Germany).
Adapting the tumour model of Suit et al. [17], 500 KHT
cells were suspended in about 50 μl PBS (phosphate
buffered saline, PAA, Parching, Austria) and were
injected subcutaneously between the cartilage and the
skin in the middle of the right ears of anaesthetised
mice. After injection the mice were continuously controlled
for tumour growth firstly by visual observation and then,
after reaching the starting size for the experiment, by using
a calliper. For the first experiments at the 200 kV X-ray
tube, the animals were included with tumour diameters of
Brüchner et al. Radiation Oncology 2014, 9:57 Page 3 of 9
http://www.ro-journal.com/content/9/1/571 – 1.5 mm. Later on, the starting size was adjusted
to 2 – 2.5 mm in order to facilitate a better handling
and positioning for the proof-of-principle experiment
at the JETI laser accelerator.
Moreover, some of the animals were sacrificed at this time
point and their tumours were extracted and immediately
frozen in liquid nitrogen. The histology of the tumours was
characterized by standard haematoxylin and eosin (H&E)
staining. Besides, the tumour microenvironment was
analysed using different immunofluorescence markers to
visualize hypoxia, perfusion and vascular endothelium. The
hypoxia marker pimonidazole (intraperitoneally, 0.1 mg g-1
body weight, dissolved at 10 mg ml-1 in 0.9% NaCl; Natural
Pharmacia Int., Research Triangle Park, NC, USA) and the
perfusion marker Hoechst 33342 (intravenously, 150 μl
per animal, 6 μg ml-1 dissolved in PBS; Sigma Aldrich,
Deisenhofen, Germany) were injected one hour and one
minute before tumour excision, respectively. For staining,
10 μm thick frozen sections of the tumours were cut,
air dried and fixed in acetone (4°C). Finally, antibodies
against pimonidazole (HydroxyprobeTM-1Mab1, clone:
4.3.11.3, 1:2500, Chemicon® Int., Temecula, Ca, USA) and
against CD31 as marker for the vascular endothelium
(cluster of differentiation 31, clone: MEC 13.3, 1:500, BD
Pharmingen, Heidelberg, Germany) were applied.
General experiment procedures
Prior to irradiation, the animals were anaesthetised
intraperitoneally with 10 mg kg-1 Xylazin (Rompun®,
Bayer Health Care GmbH, Leverkusen, Germany) and
100 mg kg-1 Ketamin (Ketamin 500 Curamed®, Curamed
Pharma, Karlsruhe, Germany). The anaesthetised animals
were positioned dorsoventral in specifically constructed
mouse setup boxes (Figure 1), and their right ears were
gently fixed at a defined position on the attached
PMMA (polymethylmethacrylate) block allowing for the
precise irradiation of the tumour [15]. The mouse setup(b)
200 kV X-rays
(a)
Figure 1 Mouse positioning at the two radiation sources. Mouse setup
200 kV X-ray tubes (a) and at the JETI laser accelerator (b). The mice were
ears on the PMMA block right outside of the box. (a) For irradiation at the
under the collimator (not shown) allowing tumour irradiation under protec
requires the tilt of the setup box so, that the right ear points downwards in
by heating up the setup boxes at JETI [15].boxes and their positioning at the 200 kV X-ray tube
and at the JETI laser accelerator, respectively, are
described below.
In parallel to the untreated controls, an additional
“0 Gy” group was introduced for all irradiation experiments.
Mice of this group were anaesthetised and positioned in
mouse setup boxes, like those of the other dose groups, but
sham irradiated. By comparing the untreated control mice,
which remain in the animal laboratory, and the “0 Gy”
groups, influences of the differing experimental procedures
should be revealed, including anaesthesia and positioning in
mouse setup boxes as well as the horizontal beam delivery
and altered environment at the JETI laser accelerator.
Animal irradiation with 200 kV X-rays
For the present experiments, a 200 kV X-ray tube of
type Maxishot 200 Y.TU/320-D03 (Yxlon Int. GmbH,
Hamburg, Germany) was used for WBI and for the
determination of appropriate doses for the treatment of
KHT sarcoma (in Dresden). The X-ray tube was operated
at 20 mA and filtered inherently with 3 mm Be + 3 mm Al
as well as with the additional 0.5 mm Cu external filter.
Absolute dosimetry was performed with a farmer ionization
chamber (Type 30010, 0.6 cm3 sensitive volume) that was
readout by an Unidos electrometer (both PTW, Freiburg,
Germany). As result, a dose rate of about 1 Gy min-1
was obtained for WBI of mice. Dose distributions and
dose homogeneities within the irradiation fields were
controlled with GafChromic EBT-1 films (ISP Corp.,
New York, NY, USA).
In addition to the filters, a collimator made up of 6 mm
Pb and of 2 mm Al was introduced. Four collimator
openings of 6 mm in diameter allow for the irradiation of
ear tumours of up to four animals protecting their bodies
against radiation. The anaesthetised mice were positioned
in setup boxes (Figure 1a) and were placed horizontally
under the collimator superimposing the fixed ears and theJETI laser electrons
boxes for mouse fixation and reproducible tumour positioning at the
placed dorsoventral in the mouse setup boxes gently fixing the right
vertical 200 kV X-ray beam the boxes were placed at defined positions
tion of the animal. (b) The horizontal electron beam delivery at JETI
to the irradiation field. Moreover, cooling of the animals was avoided
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position was 0.95 Gy min-1. In the first trial, the animals
were allocated in five different dose groups (0 Gy (4 mice),
3.8 Gy (8), 7.6 Gy (10), 9.5 Gy (8), and 13.2 Gy (7)) and
one group for tumour growth control (untreated, (8))
in order to find a suitable dose range for subsequent
irradiation studies.
Experiments with laser accelerated electrons
The electron pulses were generated in a vacuum target
chamber using the 30 TW laser system JETI [13,14] that
delivers 28 fs short laser pulses (700 mJ energy, 800 nm
central wave length) at a pulse frequency of 1 Hz. The
laser pulses were focused into a hydrogen gas jet producing
plasma and accelerating electrons in forward direction to a
broad energy spectrum with maximum energies of a few
10 MeV. In the following, a permanent magnet system
consisting of two dipole magnets (B = 0.06 T) of opposing
polarity was used to filter out the radiobiological more
effective low-energy electrons (< 3 MeV). After filtration,
the electron beam enters the purpose-built irradiation
setup that includes beam transport and control, tumour
positioning and dosimetry, as described more detailed
in Schürer et al. [15]. Briefly, the electron beam was
collimated by a 118 mm long aluminium block with
an aperture of 10 mm, prior exiting through a 1 mm
thick aluminium vacuum window to propagate in air
to the point of irradiation.
Based on previous experiments [5,18,19] a beam control
and dosimetry system, consisting of a Bragg Peak chamber
(PTW), a Faraday cup (200 mm steel, in house development
and manufacturing), Gafchromic EBT-2 dosimetry
films (ISP Corp., New York, NY, USA) and two electron
spectrometers, was applied. For real-time beam monitoring
the Bragg Peak transmission ionization chamber and the
Faraday cup were deployed both providing online dose
information via readout with an Unidos electrometer
(PTW) and a 2.5 GHz Digital Phosphor Oscilloscope (DPO
7254, Tektronix Inc., Beaverton, OR, USA), respectively.
Located in front of tumour position, EBT-2 dosimetry films
were used to control the dose homogeneity over the
irradiated field of about 5 mm in diameter during beam
optimization and for animal irradiation. Moreover, EBT-2
films in front of each tumour allow for a retrospective
determination of absolute dose administered to each
individual tumour. For this, the films were calibrated
for high energy electrons and readout with an Epson
Perfection flatbed scanner (V750pro, Epson, Germany)
[20]. Electron spectra in real-time were obtained by means
of the scintillator spectrometer (in-house production, liquid
scintillator BC 517H, Saint-Gobain, Valley Forge, USA),
where the scintillation light was monitored in up to 40 cm
water equivalent thickness (by CCD camera) providing
information on the depth dose distribution and with it onthe electron spectrum. Additionally, information on the
low-energy part (E < 20 MeV) was ascertained by means of
the mini-spectrometer. Here, the laser electrons were
deflected by permanent magnets and the resulting spot
positions, i.e. deflection angles, on EBT-2 films were used
to reconstruct the spectrum retrospectively. To control the
electron beam parameters, the two spectrometers and the
Faraday cup were moved to beam position between animal
irradiation. The Bragg Peak transmission chamber had a
fixed position and was operated in parallel to the Faraday
cup, the scintillator and to animal treatment.
For the experiments at JETI, the animals were transported
from Dresden to Jena two days after injection and housed
in the animal laboratory there. As a consequence of the
preceding 200 kV X-ray experiments, the animals were
randomly allocated in the group for tumour growth
control (untreated, (7)) and in two dose groups (0 Gy
(2) and 14 Gy (9)), which were applied at the JETI
laser accelerator as well as at the local 200 kV X-ray
tube (see below), respectively. For treatment at JETI, the
anaesthetised mice were positioned in the corresponding
mouse setup boxes (Figure 1b), which were tilted ahead
so, that the mouse lies sideways and the tumour bearing
ear points downwards allowing for tumour irradiation at
the horizontal electron beam. Then, the turned box
was placed in a movable docking station enabling a
reproducible positioning of both, the holder and the
tumour, at beam position. Positional changes of the
tumour that may arise from tilting were observed by a
CCD camera and corrected before irradiation. Moreover,
the mouse setup boxes applied at JETI exhibited an
additional lead collimator (aperture 6.5 mm) just
above the tumour position to shield the animal from
scattered radiation. The whole procedure at JETI, includ-
ing preparation, transport, positioning and treatment, took
about 20 min per mouse.
In parallel to the experiment with laser accelerated elec-
trons 200 kV X-ray reference irradiation was performed in
the local animal laboratory located in the adjacent building
to the laser laboratory. As for the preceding experiments in
Dresden, a 200 kV X-ray tube of type Maxishot 200
Y.TU/320-D03 (Yxlon Int. GmbH, Hamburg, Germany)
was applied using the same tube parameters (20 mA, filter:
3 mm Be + 3 mm Al + 0.5 mm Cu) and an identical setup,
including mouse setup boxes and additional collimator for
animal irradiation, to deliver doses of 0 Gy (2 mice) and
14 Gy (3) to the mice.
After the experiment, all animals inclusive those not
included in the experiment were brought back to Dresden,
where the follow up took place.
Follow up and analysis of tumour growth data
Tumour diameters were measured three times a week
and the corresponding tumour volumes were calculated
Figure 2 Exponential tumour growing of KHT mouse sarcoma.
Exemplary growth curve of one KHT mouse sarcoma after injection of
500 KHT cells between the cartilage and the skin of the right mouse
ear. The volume increase is shown in dependence on time starting at
the tumour size at start of treatment; exponential growing is indicated
for tumour volumes between 5 and 200 mm3 (grey coloured area).
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the longest and b the shorter tumour axis perpendicular
to a. The animals were sacrificed when the tumour
reached the diameter (i.e. a) of about 10 mm or when the
animal seemed to suffer. In order to assess the tumour
growth delay between non-irradiated and irradiated
animals, the time spans required to achieve the same
relative volume increase after inclusion in the experiment
were compared. Additionally, tumour volume doubling
times (VDT) were estimated in the tumour volume range
between 5 and 200 mm3.
For the graphical representation of tumour growth
curves and the analysis of growth delay the software
Microsoft Office Excel 2003 (Microsoft Corp., Redmond,
WA, USA) was applied. Statistical analysis was performed
using Student’s t-test and the Welch correction
implemented in the software GraphPad Prism (Vers. 4,
GraphPad Software Inc., La Jolla, CA, USA). Values
of p < 0.05 were considered as statistically significant.
Results
Growth rates und tumour growth behaviour
In a first test, the number of KHT cells in the 50 μl
injection volume was varied between 500 and 10000
cells to find the optimum number for a reproducible
and stable growth of a single tumour on the ear. KHT
cells showed a high tumour take rate, and the minimum
number of 500 cells was used in the following to reduce
unintended reflux of the injected cell suspension. Based
on daily controls first tumour growth was observed from
day 11 after injection. Besides, 45 out of 46 animals
developed tumours of 1–1.5 mm in diameter, most of
them between days 11 to 15 after injection. Exponential
tumour growth with tumour VDT of 1.5 – 3 days was
found for volumes of up to 200 mm3 (Figure 2).
By means of standard H&E staining the tumour
histology, i.e. mouse sarcoma, was confirmed. The
tumours were found to be solid and circumscribed
(Figure 3a), growing subcutaneously without infiltration of
the skin. Necrotic areas were not detected (Figures 3b
and c). Using immunofluorescence analysis (Figure 3d)
evenly distributed perfused areas, but also larger hypoxic
regions were revealed. Tumour vessels were observed
mainly in perfused, but also in unperfused, hypoxic areas.
Dose range specification
Sufficient studies on tumour growth delay require the
definition of reasonable radiation doses leading to a
significant growth delay compared to untreated tumours,
but no permanent tumour control. The VDT obtained for
the KHT tumours after 200 kV X-ray treatment in Dresden
are summarized in Figure 4, displaying a dose-dependent
retardation of tumour growth. Correspondingly, Figure 5
shows a clear tumour growth delay, measured as the timenecessary to reach for example 10fold the volume at time
of treatment in comparison to the untreated controls. For
doses higher than 7.6 Gy this increase was significant with
p-values of p = 0.013 at a dose of 9.5 Gy and p = 0.015 at
the highest dose of 13.2 Gy, respectively. No radiation side
effects and no tumour control were noticed for the whole
dose range. No differences in VDT or tumour growth delay
were detected between the untreated control group and
the sham irradiated group. Consequently, the handling
procedure at the 200 kV X-ray tube, i.e. anaesthesia,
positioning and persistence in the mouse setup boxes,
has no additional impact on tumour growth.
Proof-of-principle experiment at JETI
After the results of the 200 kV X-ray study a dose of
13.2 Gy should also be applied at the experiments in
Jena. However, for technical reasons, the highest dose
was adjusted to 14 Gy for both the irradiation with
laser accelerated electrons and with 200 kV X-rays,
respectively. The sham irradiated “0 Gy” dose groups
were retained, since the laboratory conditions and the
animal positioning were clearly different at the two
radiation sources.
At JETI the prescribed dose of 14 Gy was delivered
with a mean dose rate of 1 Gy min-1 by few hundreds
of laser accelerated electron pulses. The retrospective
determination of absolute dose administered to an indi-
vidual tumour by GafChromic EBT-2 film comes along
with an overall dose uncertainty of 8%, whereas a
dose uncertainty of 5% was linked with a single film
dose measurement. Furthermore, a maximum dose
Figure 3 Characterization of the tumour micromilieu at starting size. Representative pictures of KHT mouse sarcoma characterized at start of
treatment with a size of 2 mm in diameter: (a) The limited and bordered tumour volume was confirmed by standard H&E staining, showing (b + c) the
integrity of cellular components by differentiating the basophil stained nuclei from the eosinophil stained cytoplasm, whereas necrosis of single cells
cannot be excluded (Figures b and c are higher magnifications of Figure a). (d) The analysis of the tumour histology revealed a well perfused tumour
(blue, Hoechst 33342) that is interspersed with small vessels (red, CD31) and some hypoxic area (green, pimonidazole).
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measured by EBT-2 dosimetry film located in front of
the tumour position for all irradiations. The depth
dose distribution was controlled by film stack irradiation
before and after mouse irradiation, showing a maximum
inhomogeneity of 3%. One prerequisite for the delivery of
the prescribed dose was the online dose monitoring
via Bragg Peak transmission chamber and the Faraday
cup. By beam tuning and dose calibration (ionization
chamber and Faraday cup readout to absolute dose)
on a daily basis before starting mouse irradiation a
maximum variation of the actual delivered dose of 5%
was achieved.
Comparing the growth curves of the unirradiated
control and the sham-irradiated “0 Gy” dose groups
obtained for the two radiation sources, no apparent
difference was observed (Figure 6). In consequence,
the whole handling procedure at JETI including the
horizontal electron beam delivery that come along with
the tilt of animal and tumour as well as the altered
conditions in a physical laboratory, has no impact on
tumour growth. The comparison of the 14 Gy growth
curves reveals no significant difference (p > 0.3) between
the times needed to reach the 5fold to 100fold volumeincrease after irradiation with laser accelerated electrons
and 200 kV X-rays, respectively (Figure 6).
Discussion
The integration of laser based proton accelerators in
radiotherapy clinics is a long-term aim that includes not
only the technological development of high intensity
lasers and new techniques for dose delivery, but also
comprehensive research on the radiobiological consequences
of the new beam quality, i.e. ultra-short, ultra-intense
particle pulses. Considering the translational research
chain [4] forgoing in vitro experiments with laser acceler-
ated protons [6-10] have to be followed by animal studies,
which are however limited by the still low proton energies
at currently available laser driven accelerators.
The present paper describes the establishment of a small
animal tumour model that allows for the penetration
by ~ 20 MeV protons. For this, an anterior mouse ear
tumour model [17] was successfully adopted. The
choice of the fast-growing KHT mouse sarcoma
model for injection was likely responsible for the very
high tumour growth rate of more than 95%. Besides
this remarkable high growth rate, the tumour model



































Figure 4 Dose dependent tumour volume doubling times for
200 kV X-ray irradiation. KHT tumour volume doubling times for
the unirradiated control (8 mice) and after irradiation with 200 kV
X-rays (0 Gy (4); 3.8 Gy (8); 7.6 Gy (10); 9.5 Gy (8); 13.2 Gy (7))
determined on basis of the tumour volume at which the animals
were included in the experiment. Compared to the unirradiated
control the VDT values for doses of 7.5 Gy and higher were
significantly increased (*p < 0.05, ***p < 0.001).

























Figure 5 Dose dependent growth delay induced by 200 kV
X-ray treatment. Tumour growth curves measured after irradiation
with 200 kV X-rays (0 – 13.2 Gy) and for the untreated control
(black curve, partly covered by the 0 Gy line). The relative volumes in
dependence on time are determined on basis of the volumes at the
start of the treatment. The numbers of animals allocated to the
different groups are given in brackets; the measured data are given as
mean value ± SEM of all animals in this particular group. The tumour
growth delay relative to the untreated control was significant (*p < 0.05,
***p < 0.001) for doses higher than 7.6 Gy for the 10fold volume increase
and for doses higher than 3.8 Gy at higher volume
increases, respectively.
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tumour growth rate analyses. Moreover, a significant
dose dependent tumour growth delay was found after
200 kV X-ray treatment, fulfilling a basic requirement for
the performance of irradiation studies. Also important for
this purpose was the absence of radiation side effects and
of tumour control, even at the highest dose of 13.2 Gy,
as well as of impacts by the experimental procedures
like anaesthesia and positioning in the mouse holder
during irradiation. Beside these outcomes, an important
technological prerequisite was the ability of the laser
system JETI to deliver such a high dose in a reasonable
time. Indeed, with the newly implemented setup for small
animal irradiation [15] and by careful tuning of the laser
parameters the irradiation times could be limited to a
few minutes minimizing the overall treatment time and
therefore reducing anaesthesia.
Considering the established tumour model in comparison
to the standard subcutaneous tumour model on mouse
legs, one obvious difference is the necessity of a small
tumour volume at the time of treatment (~ 5 mm3) and
the corresponding tumour diameter of approx. 2 mm that
allows for the penetration by ~ 20 MeV protons. By
contrast, considerably higher tumour diameters of about
7 mm and tumour volumes of ~ 180 mm3 are routinelyused for the standard model [21-24]. One question arising
in this context deals with the constitution of the tumour
and its microenvironment. Investigating tumours at the
size of 5 mm3, immunofluorescence analysis revealed
that already the small tumours used in the present
experiments interact with the surrounding tissue and
activate endothelial cells to form vessels. And, similar to
larger tumours, the KHT sarcomas also generate hypoxia,
which might explain their relatively high radioresistance
with a tumour control dose higher than 14 Gy.
Finally, after fulfilling all the biological and technological
requirements [14,15], a proof-of-principle experiment at a
laser accelerator was performed using the laser facility
JETI in Jena. Since the main goal of this study was the
validation of the tumour model under realistic conditions
at a laser accelerator, only two dose values were applied
(sham “0 Gy” and 14 Gy). One important issue for the
evaluation of the suitability of the model at an experimen-
tal laser accelerator was the impact of the experimental
conditions that clearly differ from those at the reference
200 kV X-ray tube. Comparing the growth curves obtained
after “0 Gy irradiation” at both radiation sources and
for the untreated control, no difference could be observed




0 Gy X-ray (2)
0 Gy JETI (2)
14 Gy X-ray (3)
14 Gy JETI (9)










Figure 6 Comparison of tumour growth after irradiation with
laser electrons and 200 kV X-rays. Time dependent relative
tumour volume increase for the untreated control, sham irradiation
with “0 Gy” and after treatment with a dose of 14 Gy by JETI laser
accelerated electrons (triangles) and by 200 kV X-rays (squares),
respectively. The numbers in brackets specify the animals allocated
to the different groups, the error bars display the corresponding
SEM to the mean value of the corresponding group. The apparently
different tumour growth rates, compared to the results displayed in
Figure 5, resulted from the different tumour diameters of 1.0 – 1.5 mm
and 2.0 – 2.5 mm defined as starting size at which the animals were
included in the experiments in Dresden and Jena, respectively.
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experiment was quite low, these data indicate that the
impact of anaesthesia and positioning in mouse setup
boxes, of the altered environment, i.e. temperature and
moisture differing from animal laboratory, and of the
horizontal irradiation at JETI on the tumour response
can be neglected. Nevertheless, this finding awaits
confirmation in ongoing full scale experiments [14].
Further full scale experiments with different radiation
dose groups are also necessary to allow drawing conclusions
on the RBE of laser accelerated electrons. For the present
proof-of-principle study the comparison of the measured
growth delays reveals by trend a higher radiobiological
effectiveness for 200 kV X-rays relative to laser accelerated
electrons, which may be explained by known higher RBE of
kV X-ray irradiation compared to MV photons [25,26] or
electrons [26].
In a next step, the new mouse ear tumour model should
be validated for experimentation with laser accelerated
protons in order to confirm the preliminary results
obtained with laser accelerated electrons and to prepare
future full scale studies with laser accelerated protons.
Moreover, the new model should also be evaluated forhuman tumours and the choice of radiobiological
endpoint should be reconsidered. For the first trial,
tumour growth delay was a simple but nonetheless
meaningful parameter, whereas tumour control studies as
more valid endpoint in clinical cancer research [27,28]
should be considered for the next translational steps.Conclusions
A small animal tumour model suitable for the irradiation
with low energy particles was established and validated
for systematic experimentation at a laser based electron
accelerator. Thereby, the translation from in vitro to
in vivo studies was for the first time realized and the
experiences and the implemented setup provide a
valuable basis for the experimentation with laser accelerated
protons.
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